Cytokinetics, Incorporated (NASDAQ:CYTK) insider Caryn Gordon Mcdowell sold 10,131 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $14.60, for a total transaction of $147,912.60. Following the completion of the transaction, the insider now owns 19,801 shares in the company, valued at approximately $289,094.60. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Caryn Gordon Mcdowell also recently made the following trade(s):

  • On Tuesday, August 8th, Caryn Gordon Mcdowell sold 11,348 shares of Cytokinetics, stock. The shares were sold at an average price of $12.47, for a total transaction of $141,509.56.

Cytokinetics, Incorporated (NASDAQ CYTK) traded up 1.73% during mid-day trading on Friday, reaching $14.70. 196,159 shares of the company’s stock were exchanged. The stock’s market cap is $788.89 million. The company has a 50-day moving average of $13.50 and a 200-day moving average of $13.36. Cytokinetics, Incorporated has a 52-week low of $8.51 and a 52-week high of $17.20.

Cytokinetics, (NASDAQ:CYTK) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.03. The business had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $5.28 million. Cytokinetics, had a negative return on equity of 14.15% and a negative net margin of 16.00%. Equities research analysts anticipate that Cytokinetics, Incorporated will post ($2.46) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Caryn Gordon Mcdowell Sells 10,131 Shares of Cytokinetics, Incorporated (CYTK) Stock” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.americanbankingnews.com/2017/09/08/caryn-gordon-mcdowell-sells-10131-shares-of-cytokinetics-incorporated-cytk-stock.html.

CYTK has been the topic of a number of research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Cytokinetics, in a research note on Friday, May 19th. ValuEngine upgraded shares of Cytokinetics, from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Zacks Investment Research raised shares of Cytokinetics, from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Tuesday, July 11th. BidaskClub raised shares of Cytokinetics, from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Finally, Morgan Stanley began coverage on shares of Cytokinetics, in a report on Monday, July 31st. They issued an “overweight” rating and a $24.00 price objective for the company. Three research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $21.30.

Large investors have recently modified their holdings of the stock. Alambic Investment Management L.P. grew its stake in Cytokinetics, by 115.9% during the first quarter. Alambic Investment Management L.P. now owns 28,500 shares of the biopharmaceutical company’s stock valued at $366,000 after acquiring an additional 15,300 shares in the last quarter. Piermont Capital Management Inc. purchased a new position in Cytokinetics, during the first quarter valued at approximately $612,000. Capital Fund Management S.A. purchased a new position in Cytokinetics, during the first quarter valued at approximately $213,000. Fox Run Management L.L.C. purchased a new position in Cytokinetics, during the second quarter valued at approximately $436,000. Finally, Gotham Asset Management LLC purchased a new position in Cytokinetics, during the first quarter valued at approximately $641,000. 71.51% of the stock is owned by institutional investors.

About Cytokinetics,

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Insider Buying and Selling by Quarter for Cytokinetics, (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.